Cancer Mutation Atlas CMA

Cancer Mutation Atlas

Studies and references

CMA brings together targeted panels, exomes, and whole genomes, spanning broad cancer cohorts and studies focused on particular diagnoses.

Studies and counts

Study coverage in the CMA workflow
StudiesFocus
AACR Project GENIE1, TCGA2, Foundation Medicine3, CPTAC4Multiple cancer types, using clinical panels or exome sequencing
OrigiMed5Pan-cancer targeted sequencing in a Chinese cohort
REBC6, ALCHEMIST7Papillary thyroid cancer and lung cancer, respectively
Prostate 10008, METABRIC9Prostate and breast cancer, respectively
IWG-MDS10, Broad CLL11, Duke DLBCL12Myelodysplastic syndromes, chronic lymphocytic leukemia, and diffuse large B-cell lymphoma

References

  1. AACR Project GENIE Consortium. AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer Discov. 2017;7(8):818–831.
  2. Ellrott K, Bailey MH, Saksena G, et al. (MC3 Working Group; Cancer Genome Atlas Research Network). Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. Cell Syst. 2018;6(3):271–281.e7.
  3. Hartmaier RJ, Albacker LA, Chmielecki J, et al. High-Throughput Genomic Profiling of Adult Solid Tumors Reveals Novel Insights into Cancer Pathogenesis. Cancer Res. 2017;77(9):2464–2475.
  4. Li Y, Dou Y, Da Veiga Leprevost F, et al. (Clinical Proteomic Tumor Analysis Consortium). Proteogenomic data and resources for pan-cancer analysis. Cancer Cell. 2023;41(8):1397–1406.
  5. Wu L, Yao H, Chen H, et al. Landscape of somatic alterations in large-scale solid tumors from an Asian population. Nat Commun. 2022;13:4264.
  6. Morton LM, Karyadi DM, Stewart C, et al. Radiation-related genomic profile of papillary thyroid carcinoma after the Chernobyl accident. Science. 2021;372(6543):eabg2538.
  7. Govindan R, Mandrekar SJ, Gerber DE, et al. ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer. Clin Cancer Res. 2015;21(24):5439–5444. (Trial design paper; ALCHEMIST has no separate GDC dataset publication.)
  8. Armenia J, Wankowicz SAM, Liu D, et al. The long tail of oncogenic drivers in prostate cancer. Nat Genet. 2018;50(5):645–651.
  9. Pereira B, Chin SF, Rueda OM, et al. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun. 2016;7:11479.
  10. Bernard E, Tuechler H, Greenberg PL, et al. Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. NEJM Evid. 2022;1(7):EVIDoa2200008.
  11. Knisbacher BA, Lin Z, Hahn CK, et al. Molecular map of chronic lymphocytic leukemia and its impact on outcome. Nat Genet. 2022;54(11):1664–1674.
  12. Reddy A, Zhang J, Davis NS, et al. Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma. Cell. 2017;171(2):481–494.e15.
← Back to the atlas overview